Is compounded tirzepatide legal in 2026?
In a narrow lane, yes. Mass compounding ended when the FDA declared the shortage resolved (late 2024) and enforcement discretion expired (February–March 2025); courts upheld the agency in May 2025. What remains legal is patient-specific compounding at licensed 503A pharmacies where the prescriber documents a clinical need an FDA-approved product cannot meet — and the FDA's April 2026 proposed rule would bar 503B facilities from bulk-compounding it entirely. "Research use only" tirzepatide sold online is not legal for human use under any framing. The dated timeline is in our regulatory explainer.
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
For orientation: the verified tirzepatide field spans $215 (NexLife↗) to $597 (LifeMD↗) per month all-in as of 2026-08-09 — a $382 spread for the same molecule, made of structure rather than chemistry — while the brand lane holds $449 at maintenance via Zepbound (LillyDirect↗). Coverage, where a plan grants it, outranks the whole board.
The reading rules behind every number above: figures are all-in (medication plus mandatory fees) at the maintenance dose; prepaid paths are labeled as upfront commitments; stated-not-verified flags mark claims we could not capture on a provider’s own pages; and each record carries its capture date, source link, and archive link so the answer can be checked rather than trusted. Recompute anything here from the public dataset — that reproducibility, not our word, is the warranty.
One structural fact worth carrying out of this page: the spread between the cheapest and most expensive verified way to be on the same molecule now exceeds $4,584 a year — all of it structure (memberships, tiers, wrap) rather than chemistry — while the brand lane keeps cutting underneath (Zepbound vials to $449 in December 2025, the oral pill to $149 in January 2026). In a market moving that fast, the durable skill is not knowing today’s answer but knowing how to re-derive it: all-in basis, maintenance dose, dated capture, recomputable source — the four checks the methodology formalizes.
Basis for every figure: all-in monthly price (medication + mandatory fees) at the maintenance dose, captured from provider pages on the dates in the database. Not medical advice.